Your search for apixaban returned 71 results

Accu-Break Pharmaceuticals (ABP) announced that the Food & Drug Administration (FDA) has accepted for filling the New Drug Application (NDA) for Warfarin Potassium.

The summary below gives an overview of some of the important additions and changes MPR has made to its drug database through the end of September. The chart below provides highlights of the 118 key monograph updates made this month (not an inclusive list).

Research presented at the European Society of Cardiology Congress 2015 reports that an education program did not improve adherence to apixaban among patients with atrial fibrillation (AF) compared to usual information about the disease and treatment.

Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).

Direct oral anticoagulants (DOACs) have distinct bleeding profiles and require individualized management approaches, according to a new review.

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Almost all the various treatment options for acute venous thromboembolism are equally safe and effective, according to a new study.

Non-vitamin K oral anticoagulants exhibit variable effects on coagulation assays, according to a new study.

Bristol-Myers Squibb and Pfizer announced results from the pre-specified secondary analysis of the Phase 3 AMPLIFY-EXT trial with Eliquis (apixaban).

Bristol-Myers Squibb and Pfizer announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy.